Capricor Therapeutics, Inc.
CAPR
$26.01
-$0.15-0.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 27.38M | 23.13M | 20.36M | 22.05M | 18.92M |
| Gross Profit | -27.38M | -23.13M | -20.36M | -22.05M | -18.92M |
| SG&A Expenses | 9.40M | 6.02M | 5.92M | 5.67M | 6.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.77M | 29.16M | 26.28M | 27.72M | 24.98M |
| Operating Income | -36.77M | -29.16M | -26.28M | -27.72M | -24.98M |
| Income Before Tax | -33.94M | -30.17M | -24.57M | -25.91M | -24.39M |
| Income Tax Expenses | -- | 1.60K | -- | -- | -- |
| Earnings from Continuing Operations | -33.94M | -30.17M | -24.57M | -25.91M | -24.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.94M | -30.17M | -24.57M | -25.91M | -24.39M |
| EBIT | -36.77M | -29.16M | -26.28M | -27.72M | -24.98M |
| EBITDA | -36.24M | -28.65M | -25.79M | -27.23M | -24.58M |
| EPS Basic | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 |
| Normalized Basic EPS | -0.37 | -0.39 | -0.34 | -0.35 | -0.33 |
| EPS Diluted | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 |
| Normalized Diluted EPS | -0.37 | -0.39 | -0.34 | -0.35 | -0.33 |
| Average Basic Shares Outstanding | 57.43M | 48.85M | 45.72M | 45.71M | 45.64M |
| Average Diluted Shares Outstanding | 57.43M | 48.85M | 45.72M | 45.71M | 45.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |